Companies in #Major Depressive Disorder

Alzamend Neuro is an Atlanta, Georgia-based clinical-stage biopharmaceutical company developing novel products for neurodegenerative and psychiatric disorders, with a focus on Alzheimer's disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder. Its two lead candidates are AL001, a patented ionic cocrystal that delivers lithium together with salicylate and L-proline and is designed to improve brain delivery and safety relative to conventional lithium, and ALZN002, a patented cell-based therapeutic vaccine intended to restore the immune system's ability to clear the pathology associated with Alzheimer's. The company was incorporated in 2016, listed on Nasdaq in June 2021, and reported positive topline data in March 2026 from a Phase II 'Lithium in Brain' study of AL001 that demonstrated bioequivalence and superior brain delivery across all measured brain regions. It initiated a Phase II trial of AL001 in bipolar disorder in March 2026 in collaboration with Massachusetts General Hospital, and in 2026 its Phase 1/2A lithium neuroimaging data were accepted for presentation at the Neuroscience 2026 annual meeting.

HMNC Brain Health is a Munich-based clinical-stage biopharmaceutical company developing personalized precision psychiatry treatments powered by AI and pharmacogenomics. Its pipeline includes two lead depression programs, one of which is an oral esketamine formulation being developed as a more convenient alternative to Johnson & Johnson's Spravato, and a separate novel mechanism in treatment-resistant depression. The company is leveraging companion-diagnostic and digital-phenotyping tools to stratify patients and improve response rates in major depressive disorder.

Neumora Therapeutics is a clinical-stage neuroscience company developing precision medicines for brain diseases with high unmet need. Its lead asset NMRA-140 (navacaprant) is a kappa opioid receptor antagonist studied in major depressive disorder, and the company has additional programs in schizophrenia and other CNS indications. Following two Phase 3 failures in mid-2026, Neumora announced a 35% workforce reduction and is discontinuing development of its lead depression asset.

Vistagen Therapeutics is a late clinical-stage neuroscience company based in South San Francisco, California, developing rapid-onset intranasal product candidates known as pherines for psychiatric and neurological disorders. Its lead asset fasedienol (PH94B) nasal spray is in Phase 3 development for the acute treatment of social anxiety disorder; the PALISADE-4 Phase 3 trial did not meet its endpoints in June 2026, and in September 2026 the company reported preliminary positive data from the study's open-label extension and said it plans to meet the FDA during the current quarter on the path forward. The company's pherine portfolio also includes itruvone (PH10) for major depressive disorder, refisolone (PH80), AV-101, PH15 and PH284. Founded in 1998, the company has operated as Vistagen Therapeutics since its 2023 rebrand from VistaGen Therapeutics and trades on the Nasdaq Capital Market.